CXCR2 and neoplasm: Administration of IL-8 antibodies via SX-682 (a small molecule inhibitor targeting CXCR1 and CXCR2) reduces the number of immunosuppressive myeloid-derived suppressor cells (MDSCs) within the tumor microenvironment and enhances the efficacy of adoptive cell therapy with NK cells (59).